UCB backs epilepsy-focused digital heath startup Nile AIBelgian drugmaker UCB has been steadily building its digital health expertise for several years, and that includes nurturing Share XUCB backs epilepsy-focused digital heath startup Nile AIhttps://pharmaphorum.com/news/ucb-backs-epilepsy-focused-digital-heath-startup-nile-ai/
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a Share XCould Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/
Synairgen starts dosing inhaled COVID-19 drug in phase 3 trialUK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after Share XSynairgen starts dosing inhaled COVID-19 drug in phase 3 trialhttps://pharmaphorum.com/news/synairgen-starts-dosing-inhaled-covid-19-drug-in-phase-3-trial/
Amgen’s Enbrel heads ICER list of unjustified US price risesUS cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and Share XAmgen’s Enbrel heads ICER list of unjustified US price riseshttps://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/
Itamar buys Spry to add wearable to its sleep apnoea detectorsIsraeli company Itamar Medical has agreed to acquire Spry Health, aiming to use the US company’s wearable technology Share XItamar buys Spry to add wearable to its sleep apnoea detectorshttps://pharmaphorum.com/news/itamar-buys-spry-to-add-wearable-to-its-sleep-apnoea-detectors/
Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio techImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from Share XOral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio techhttps://pharmaphorum.com/news/oral-covid-19-vaccine-beckons-as-immunitybio-licenses-iosbio-tech/
EMA says AstraZeneca’s COVID-19 shot could be approved on 29 JanuaryThe European medicines Agency (EMA) said this morning it has received a marketing application from AstraZeneca for its Share XEMA says AstraZeneca’s COVID-19 shot could be approved on 29 Januaryhttps://pharmaphorum.com/news/ema-says-astrazenecas-covid-19-shot-could-be-approved-on-29-january/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
Bioclinica boosts digital trial credentials with Saliency buyWith the ink barely dry on its last merger agreement, clinical trial and imaging specialist Bioclinica is on Share XBioclinica boosts digital trial credentials with Saliency buyhttps://pharmaphorum.com/news/bioclinica-boosts-digital-trial-credentials-with-saliency-buy/